SIKA EXPANDS PRESENCE IN ECUADOR WITH A NEW PLANT
With the opening of the new plant in Quito, Sika further strengthens its presence and proximity to customers in Ecuador. This strategic investment enhances Sika's ability to tap into Ecuador's full market potential for its mortar solutions, which will be primarily used for interior walls and tile adhesives.
Sika already operates a mortar production facility in southern Ecuador, in the economic area of Guayaquil, the largest city in the country. Up until now, the Quito region in the north has been supplied from this location. With the new plant in Quito, Sika will optimize its nationwide supply chain with shorter transportation routes to serve customers more efficiently and reduce the carbon footprint.
Sika is well known in Ecuador and around the world for its innovative and high-performance solutions for the construction industry. Having been locally present in the country since many decades, Sika is a trusted partner to customers in all market segments. The presence and product offering for tile adhesives were significantly strengthened by the acquisition of Parex in 2019 and since then, Sika has built up a leading position for tile setting materials and mortars in Ecuador.
Mike Campion, Regional Manager Americas: 'Our new plant in Quito comes at a pivotal moment as Ecuador experiences a strong rebound in construction activity. Sika is well positioned to supply the growing markets in both the North and South of the country with high-quality, innovative solutions.'
After a three-year downturn, Ecuador's construction industry is poised for recovery, with an expected average annual growth rate of 4.3% up to 2028. This recovery will be driven by investment in mining, transportation, electricity infrastructure, as well as residential construction projects.
SIKA CORPORATE PROFILESika is a specialty chemicals company with a globally leading position in the development and production of systems and products for bonding, sealing, damping, reinforcing, and protection in the building sector and industry. Sika has subsidiaries in 102 countries around the world, produces in over 400 factories, and develops innovative technologies for customers worldwide. In doing so, it plays a crucial role in enabling the transformation of the construction and transportation industries toward greater environmental compatibility. Its 34,000 or so employees generated annual sales of CHF 11.76 billion in 2024.
CONTACTDominik SlappnigCorporate Communications &Investor Relations+41 58 436 68 21slappnig.dominik@ch.sika.com
The media release can be downloaded from the following link:Media Release.pdf
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
5 days ago
- Business Upturn
Santhera extends Highbridge convertible bond to 30th September 2025
By GlobeNewswire Published on August 15, 2025, 10:00 IST Ad hoc announcement pursuant to Art. 53 LRA Pratteln, Switzerland, 15 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that by mutual agreement the Company and Highbridge Capital Management, LLC (Highbridge) have decided to extend the maturity date of the existing CHF 7 million private convertible bond, that has a strike price of CHF 10.00, to 30th September 2025. About Santhera Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE® (vamorolone), a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Medicines Agency (EMA), in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), in China by the National Medical Products Administration (NMPA) and Hong Kong by the Department of Health (DoH). Santhera has out-licensed rights to AGAMREE for North America to Catalyst Pharmaceuticals and for China and certain countries in Southeast Asia to Sperogenix Therapeutics. For further information, please visit AGAMREE® is a trademark of Santhera Pharmaceuticals. For further information please contact: Santhera Catherine Isted, Chief Financial Officer: [email protected] ICR Healthcare [email protected] Disclaimer / Forward-looking statements This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements. # # # Attachment 250815 Highbridge Convertible Bond_ENGLISH_FINAL Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
5 days ago
- Yahoo
Komax Holding First Half 2025 Earnings: CHF0.68 loss per share (vs CHF0.49 profit in 1H 2024)
Komax Holding (VTX:KOMN) First Half 2025 Results Key Financial Results Revenue: CHF278.3m (down 13% from 1H 2024). Net loss: CHF4.60m (down by 283% from CHF2.52m profit in 1H 2024). CHF0.68 loss per share (down from CHF0.49 profit in 1H 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Komax Holding Earnings Insights Looking ahead, revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Machinery industry in Switzerland. Performance of the Swiss Machinery industry. The company's shares are down 19% from a week ago. Risk Analysis Before you take the next step you should know about the 1 warning sign for Komax Holding that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Tom's Guide
5 days ago
- Tom's Guide
Proton refuses to be 'held hostage' by controversial Swiss surveillance law
Proton has said it is moving most of its physical infrastructure out of Switzerland due to concerns surrounding the country's proposed surveillance law. Its new Lumo AI assistant is the first product to move, as it looks to invest in, and embrace, the wider European continent. This would impact all of Proton's privacy-focused products, including Proton VPN – one of the best VPNs we've tested. Back in May, Proton CEO Andy Yen initially hinted that the provider could leave Switzerland if the surveillance law was passed. Traditionally, Swiss privacy laws have been very strong but revisions to its encryption law are proposing increased surveillance obligations, data collection, and user identification. The law's amendments are yet to be approved but Proton isn't taking any chances. Proton won't be moving all of its physical infrastructure out of Switzerland straight away, with a phased approach being taken. The decision was first noted in Proton's announcement of Lumo – its new, privacy-focused, AI assistant. It said "because of legal uncertainty around Swiss government proposals to introduce mass surveillance – proposals that have been outlawed in the EU – Proton is moving most of its physical infrastructure out of Switzerland. Lumo will be the first product to move." Proton will continue its fight against the proposed surveillance law and argued it would be "extremely damaging to the Swiss economy." However it is also embracing the wider European continent and shifting Lumo out of Switzerland represents a €100 million plus investment into the EU. Speaking at the time of Lumo's launch, Andy Yen said its infrastructure will be located in Germany. Proton is also developing facilities in Norway, at a cost of CHF 100 million. The Proton team commented under a Reddit post clarifying its position. It said: "Proton's infrastructure is being diversified to Europe, so if the Swiss legal revision that we are opposing succeeds, Proton can't be held hostage by Switzerland by having all of our immovable server infrastructure stuck in the country." It added that Proton, and all of its products, remain under Swiss jurisdiction for now. It's important to clarify that although dangerous privacy laws are being proposed, they haven't yet been approved. As it stands, Switzerland's privacy laws remain strong and all Proton products continue to reap the benefits of this. It will continue to protect users with high standards of encryption, audited no-logs policies, and class-leading security. The proposed Swiss encryption laws have led to strong debates and cloud security company Infomaniak clashed with Proton over it. Infomaniak accused Proton of having a "lack of knowledge of Swiss political institutions" but subsequently released a statement saying it opposed the law's revision in their current form. The law seeks to collect and store user information, including metadata. Significant identifiable information can be harvested from metadata and this would seriously undermine services offering any type of encrypted communication. Threema and NymVPN are two other Swiss-based privacy providers that have opposed the law. The latter expressed its fundamental opposition to the changes in a detailed statement back in April 2025. We test and review VPN services in the context of legal recreational uses. For example: 1. Accessing a service from another country (subject to the terms and conditions of that service). 2. Protecting your online security and strengthening your online privacy when abroad. We do not support or condone the illegal or malicious use of VPN services. Consuming pirated content that is paid-for is neither endorsed nor approved by Future Publishing.
